VCEL · Q3 2025 results

Vericel Corporation Q3 2025 Earnings Recap

Published November 6, 2025

Vericel Corporation reported a record third quarter in 2025, driven by impressive revenue growth and significant profit improvements, highlighting strong momentum in its MACI and burn care products.

The numbers

Reported results against what analysts expected.

Earnings per share $0.10 vs $-0.02 expected · beat by 600.0%
Revenue 67503000 vs 92664000 expected · missed by 27.2%
Nov 6 to Nov 13 +2.81% the days after
Nov 6 to Dec 9 -0.95% the weeks after

Key takeaways

From the Q3 2025 earnings call.

  • Third quarter total revenue reached a record $67.5 million, exceeding guidance, with MACI revenue increasing 25% year-over-year to $55.7 million.
  • Adjusted EBITDA margin stood at 25%, with GAAP net income surpassing $5 million and operating cash flow exceeding $22 million.
  • The launch of MACI Arthro has resulted in a substantial increase in biopsy growth, with over 800 trained surgeons, enhancing overall implant and revenue growth.
  • Expansion into international markets, including a planned MACI launch in the U.K. by 2027, positions the company for long-term growth.
  • Continued sales force enhancements and strategic investments in marketing and operations are set to further strengthen MACI's leadership in knee cartilage repair.
Your portfolio

Track earnings for the stocks you own

Add your portfolio once, by connecting your broker or importing your history. When a company you hold reports, you get a recap like this one by email, with how the stock moved.

Also published on November 6, 2025

This summary was written by AI from the official earnings call transcript. It is for information only and is not financial advice. For VCEL's price history and fundamentals, see the VCEL stock page.